Discovery of PFI-6, a small-molecule chemical probe for the YEATS domain of MLLT1 and MLLT3.
Raux, B., Buchan, K.A., Bennett, J., Christott, T., Dowling, M.S., Farnie, G., Fedorov, O., Gamble, V., Gileadi, C., Giroud, C., Huber, K.V.M., Korczynska, M., Limberakis, C., Narayanan, A., Owen, D.R., Saez, L.D., Stock, I.A., Londregan, A.T.(2023) Bioorg Med Chem Lett 98: 129546-129546
- PubMed: 37944866 
- DOI: https://doi.org/10.1016/j.bmcl.2023.129546
- Primary Citation of Related Structures:  
8PJ7, 8PJI - PubMed Abstract: 
Epigenetic proteins containing YEATS domains (YD) are an emerging target class in drug discovery. Described herein are the discovery and characterization efforts associated with PFI-6, a new chemical probe for the YD of MLLT1 (ENL/YEATS1) and MLLT3 (AF9/YEATS3). For hit identification, fragment-like mimetics of endogenous YD ligands (crotonylated histone-containing proteins), were synthesized via parallel medicinal chemistry (PMC) and screened for MLLT1 binding. Subsequent SAR studies led to iterative MLLT1/3 binding and selectivity improvements, culminating in the discovery of PFI-6. PFI-6 demonstrates good affinity and selectivity for MLLT1/3 vs. other human YD proteins (YEATS2/4) and engages MLLT3 in cells. Small-molecule X-ray co-crystal structures of two molecules, including PFI-6, bound to the YD of MLLT1/3 are also described. PFI-6 may be a useful tool molecule to better understand the biological effects associated with modulation of MLLT1/3.
Organizational Affiliation: 
Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7FZ, UK; Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7FZ, UK.